Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Patent: 5,484,801

« Back to Dashboard
Patent 5,484,801 protects KALETRA and NORVIR and is included in two NDAs. There have been zero Paragraph IV challenges on Norvir and There are eight tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Protection for KALETRA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifteen patent family members in fourteen countries.

Summary for Patent: 5,484,801

Title: Pharmaceutical composition for inhibiting HIV protease
Abstract:A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a mixture of (1) (a) a solvent selected from propylene glycol and polyethylene glycol or (b) a solvent selected from polyoxyethyleneglycerol triricinoleate, polyethylene glycol 40 hydrogenated castor oil, fractionated coconut oil, polyoxyethylene (20) sorbitan monooleate and 2-(2-ethoxyethoxy)ethanol or (c) a mixture thereof and (2) ethanol or propylene glycol.
Inventor(s): Al-Razzak; Laman A. (Libertyville, IL), Marsh; Kennan C. (Lake Forest, IL), Manning; Lourdes P. (Grayslake, IL), Kaul; Dilip (Waukegan, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:08/440,277
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound;
Patent PDF download available with subscription

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Abbvie
KALETRA
lopinavir; ritonavir
SOLUTION;ORAL021251-001Sep 15, 2000RXYes5,484,801*PED<disabled>
Abbvie
NORVIR
ritonavir
SOLUTION;ORAL020659-001Mar 1, 1996RXYes5,484,801*PED<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,484,801

Country Document Number Publication Date Supplementary Protection Certificate SPC Country SPC Expiration
Hong Kong1011609Oct 11, 2002
Canada2178632Aug 03, 1995
Spain2169121Jul 01, 2002
Austria210441Dec 15, 2001
South Korea100360963Feb 11, 2003
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc